Pharma outsourcing: people on the move

By Phil Taylor

- Last updated on GMT

Outsourcing-Pharma.com presents its periodic round-up of executive appointments in the contract services sector and pharmaceutical industry.

AstraZeneca​’s chief executive, David Brennan​, was elected board chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) at the industry group's annual meeting on April 3.

UK contract research organisation (CRO) Cyprotex​ has appointed Simon Bury​ as its chief commercial officer. Bury joins Cyprotex from Shanghai ChemPartner, where he was director of business development.

Ecron Acunova​, a CRO operating out of Germany, India and the US, has named Dr. Antal Hajos​ as managing director and CEO Europe. Hajos will have overall responsibility for all business, strategic and operational aspects of the European operations.

Health Decisions​, a CRO specialising in adaptive solutions for clinical development, has named Rich Podurgal​ as its chief human resources officer.

Piramal Healthcare​ has appointed Nandini Piramal​ on the board of the company as an executive director.

Sygnature Chemical Services​ of the UK, which provides of medicinal and synthetic chemistry and chemical library services, has named Dr. Paul Clewlow​ as senior vice president, business development, and as an executive member of its board of directors.

At eClinical specialist Phase Forward,Christopher Menard​, formerly vice president of finance, has succeeded Rodger Weismann​ as senior vice president and chief financial officer.

At India’s Wockhardt, Habil Khorakiwala​ has stepped down from the managing director post in favour of his son Murtaza Khorakiwala​. Meanwhile another son, Hozaifa Khorakiwala​, has been named an executive director of the firm.

Bioprocessing company Xcellerex​ has appointed David Williams​, retired chairman and CEO of Sanofi Pasteur, to its board of directors.

Seigo Kashii​, has been appointed president and CEO of the North American subsidiary of Astellas Pharma​. His predecessor, Yoshihiko Hatanaka​, will become the chief strategy officer and chief financial officer at Astellas Pharma in Japan.

Related topics: Contract Manufacturing

Related news

Show more